Attempts to control bacillary dysentery have met with varying degrees of success in different parts of the world. In areas where the disease is no longer of significant importance, public health procedures probably have been responsible for the decrease in morbidity. The necessary public health facilities and skills will soon be available in many countries; however, in others, they will be achieved only after many years, and, during this time, bacillary dysentery will continue to remain a significant problem.
Immunization, if it could be attained, would be a logical way to control bacillary dysentery in areas with inadequate public health facilities. Efforts in this direction, however, have not been successful (Hardy, DeCapito, and Halbert, 1948; Higgins, Floyd, and Kadar, 1955) . There is some evidence that individuals, after having recovered from bacillary dysentery, are resistant for an unknown period of time to subsequent attacks by an organism of the same serotype (Hardy and Watt, 1944; Cruickshank, 1963) . In view of this, the use of orally administered living vaccines might be considered, and the question of what characteristics such preparations should possess necessarily arises.
We have already identified the sequence of events which occur in the pathogenesis of a severe dysentery infection (LaBrec et al., 1964; Formal et. al., 1965) . These steps consist of penetration of the intestinal epithelial cell by the dysentery bacillus, entrance into the lamina propria, followed by a period of intensive bacterial multiplication which generally leads to ulcer formation. Any decrease in the infecting organism's ability to complete any one of these steps must render it less virulent. Mutant strains have been isolated which have lost the capacity to penetrate the intestinal epithelium. When these strains are fed to starved guinea pigs or monkeys, the animals react no differently than if they had received nonpathogenic strains of Escherichia coli (LaBrec et al., 1964) . Presently, we consider such mutant strains to be avirulent.
Shigella flexneri strains which have incorporated the rha+ xyl+ region of the E. coli chromosome can penetrate the intestinal epithelium and enter the lamina propria, but are unable to undergo further multiplication. Although these hybrid strains fail to kill starved guinea pigs, they do cause an inflammatory reaction of the intestinal mucosa which, however, does not proceed to ulceration and subsides in approximately 4 days. When fed to monkeys, the hybrid strains fail to cause any apparent symptoms but are capable of producing a mild intestinal inflammation (Formal et al., 1965) . We consider these hybrid strains to be attenuated. (Formal et al., 1965 We calculated exact probabilities for a 2 X 2 contingency table using the factorial method, as described by Batson (1956) .
Serological tests. The latex particle agglutination test was used to detect antibody in serum and in stool specimens. A 10% dilution of latex particles (Difco) was prepared in saline. Somatic antigen, prepared from S. flexneri 2457T by the method of Goebel, Binkley, and Perlman (1945) , was added to the latex suspension at a final concentration of 20 ,g/ml, and this suspension was incubated for 1 hr at 37 C. The sensitized latex particles were then washed three times in saline and diluted to yield a 1:40 dilution of the original commercial preparation. Agglutination tests were performed by adding 0.1 ml of sensitized latex particles to 0.9 ml of twofold serial dilutions of serum or stool extract. The agglutination tests were incubated at 52 C for 1 hr, followed by incubation at room temperature overnight.
For coproantibody determinations, monkeys were placed in restraining chairs and fed 7.5 g of MgSO4 dissolved in 20 ml of tap water (Freter, 1962b) . Within 2 to 3 hr after this treatment, the animals developed a voluminous diarrhea. Fresh diarrheal stool was collected and centrifuged at 4 C; the supernatant fluid was removed, frozen, and stored at -20 C. In this manner, pre-and postvaccine stools were collected and were subquently assayed for antibody at the same time. RESULTS Preliminary experiments with small groups of animals indicated that 28 daily doses of the a The two doses of vaccine were fed at an interval of 3 days, and animals (test and control) were challenged 10 days after the last vaccine dose was administered.
b Symptoms consisted of either a severe propulsive diarrheal or classical bacillary dysentery with blood in the diarrheal stool.
c p = 0.0003. d P = 0.02. e Group 1 versus group 2, P = 0.6; groups 1 and 2 versus group 3, P = 0.0003. avirulent mutant strain 24570 rendered animals resistant to infection with the virulent 2457T strain. In subsequent experiments, 22 monkeys were immunized orally with five doses of a mutant, avirulent strain of S. flexneri 2a; 21 uninoculated monkeys were used as controls. The doses were administered to the test monkeys at 3-day intervals, and, 10 days after the last dose, both groups of animals were challenged with the virulent, parental strain of S. flexneri 2a. None of the 22 immunized monkeys exhibited symptoms consisting of severe, propulsive diarrhea or classical dysentery with blood in the diarrheal stool, whereas 7 of the 21 control monkeys did exhibit such symptoms (2 of these 7 died). These results indicate that, under the prescribed conditions, significant (P = 0.004) protection can be achieved against clinical symptoms. The administration of the vaccine did not appear to affect the viability of the challenge strain in the bowel, because isolation of the virulent S. flexneri 2a challenge was made with equal frequency in both the immunized and the control animals. When three doses of the vaccine were administered to six monkeys at 3-day intervals, and the animals were challenged 10 days after the last dose, evidence of protection was not obtained. Three of the six monkeys exhibited the symptoms described above and eventually died. During this experiment, another five-dose regimen was tested in five monkeys, and, as in the previous experiments, none of the monkeys exhibited clinical symptoms.
We have not yet conducted an experiment in which the three-dose regimen of vaccine is administered over the same time span (ca. 2 weeks) as the five-dose regimen.
Experiments similar to those just described were also conducted with the E. coli K-12-S. flexneri 2a hybrid strain as a vaccine. In the first experiment, the effect of five oral doses of the hybrid-strain vaccine or five oral doses of acetone-killed and dried (AKD) cells (30 mg per dose) was investigated. The immunizing doses were fed at 3-day intervals, and the animals were challenged 10 days after the last vaccine dose with the virulent strain of S. flexneri 2a. None of the eight monkeys given the five-dose regimen of the hybrid-strain vaccine developed clinical symptoms, whereas three of the eight monkeys given five doses of AKD cells did exhibit severe symptoms. Of nine monkeys in an uninoculated control group, five exhibited symptoms, and two of these five eventually died (hybrid-strain vaccine group versus control group, P = 0.02). This experiment demonstrated that the hybrid vaccine conferred a significant degree of resistance on those animals receiving it.
Three experiments were conducted to determine whether only one or two doses of the hybrid vaccine was sufficient to render animals resistant to challenge with the virulent strain of S. flexneri 2a. The results (Table 2) demonstrate that animals receiving even one dose of the hybrid vaccine were significantly more resistant to challenge than were control animals. Moreover, there was no significant difference in the response of challenged animals which received either one or two doses of the hybrid vaccine. The results of all tests in which monkeys were fed either five doses of the mutant or one or more doses of the hybrid strain of S. flexneri 2a, and then challenged with virulent S. flexneri 2a, may be summarized as follows. Of the 94 monkeys that received vaccine, only 3 exhibited clinical symptoms, whereas 46 of 97 uninoculated control-group monkeys did develop these symptoms (P = 0.00001).
Two experiments were carried out to test the specificity of the induced resistance. In the first experiment, two groups of five monkeys each were fed five doses of strain 24570 vaccine and, together with control animals, were challenged with either the virulent 2457T strain of S. flexneri 2a or a heterologous, but serologically related, virulent strain of S. flexneri lb. In the second experiment, two groups of animals which had received two doses of the hybrid-strain vaccine, together with controls, were challenged with the virulent strain of either S. flexneri 2a or S. flexneri 6. Table 2. t Three of the four animals died.
The results of this study are summarized in Table 3 . In both experiments, evidence for resistance to homologous challenge was obtained, but neither experiment yielded any evidence for heterologous protection. When the data from both experiments were pooled, statistically significant evidence was obtained that a degree of specificity was involved in the resistance conferred by the vaccines.
Serum and coproantibody studies were carried out on a limited number of animals receiving either five doses of the avirulent mutant or two doses of the attenuated hybrid vaccines. In each case, serum or diarrheal stool (obtained by use of orally administered magnesium sulfate) was collected before the vaccine was fed and 7 days after the last vaccine dose. The results of this study are presented in Table 4 . All the monkeys tested had prevaccination serum antibodies. Three of eleven animals which received five doses of the mutant strain had greater than a one-tube rise in serum antibody titer. None of five animals fed two doses of the hybrid strain exhibited a rise in serum antibody titer. We were not able to detect a coproantibody response in any of the animals which received the vaccines.
DIscussIoN
The two strains used in this study possess the characteristics which we presently consider to be typical of avirulent and attenuated dysentery bacilli. The avirulent mutant causes neither symptoms nor histological changes in the bowel mucosa; the attenuated strain does not provoke The mechanism of this induced resistance is not known at present. Neither of the vaccines produced consistent rises in serum antibody or detectable levels of coproantibody. Possibly, the latex particle agglutination test is not sufficiently sensitive to detect low levels of coproantibody. Freter (1962b) emphasized the difficulties of detecting antibody in feces and suggested the use of the Farr (1958) test for this purpose (Freter, 1962a) . We attempted to prepare Farr-test antigen from S. flexneri 2a but were not able to obtain suitable preparations (LaBrec and Formal, unpublished data). Because of this, we must still consider the possibility that coproantibody plays a role in the induced resistance which was observed.
It seems likely that antigen must pass through the intestinal epithelium to induce the resistance that we observed in the present investigation. In the case of the avirulent mutant, any antigenic material probably is absorbed in an inconsistent and unpredictable fashion, and repeated large doses of dead bacteria probably would produce the same effect (Freter and Gangarosa, 1963; Rauss and Ketyi, 1964) . On the other hand, the hybrid strain invades the bowel mucosa, carrying with it antigenic material, and a single dose was sufficient to confer protection under the conditions of our test system.
When it is established satisfactorily that resistance can be induced, the risks involved in feeding the vaccine strains must be considered. Several experimental models are available to test the safety of vaccine strains. The ability to cause ulcerative lesions of the cornea or to penetrate HeLa cells seems to correlate well with the capacity of an organism to penetrate the intestinal epithelial cell. [Occasionally, strains which will not penetrate the intestinal epithelial cell will be observed to enter HeLa cells. These strains invariably possess fimbriae (as indicated by their ability to agglutinate guinea pig red blood cells; Duguid and Gilles. 1957 ) which allow the organism to stick to the HeLa cell and gain entrance to this cell by a process apparently different from that of virulent bacilli (LaBrec and Formal, unpublished data) .] The inability of a strain to penetrate the intestinal epithelium can be confirmed further by feeding the organisms to monkeys and guinea pigs. Present tests for the safety of the attenuated hybrid strains depend on their inability to cause a fatal infection when fed to starved guinea pigs or to produce diarrheal symptoms in monkeys. These strains should penetrate HeLa cells; most retain the ability to cause keratoconjunctivitis, and all should produce inflammatory changes in the intestinal mucosa. As more experiments are carried out, other criteria for assessing vaccine safety undoubtedly will become available.
The present investigation is, of course, preliminary in nature. Several obvious investigations are presently under consideration: (i) use of a reduced number of bacteria per dose; (ii) length of the induced immunity; (iii) use of multiple serotypes in a single dose; (iv) efficacy of the vaccine under conditions of natural exposure.
